Ho-RadioEmbolizaTiOn Using personalized prediCtive dosimetry in patients with Hepatocellular carcinoma: A prospective, single-centre study (RETOUCH).

Background And Aims: Holmium-166 (Ho) radioembolization could offer a more individualized approach in terms of imaging and dosimetry. We aim to evaluate the feasibility and safety of Ho selective internal radiation therapy (SIRT) using a higher tumour dose than previously administered determined by Ho-scout as a surrogate marker in HCC patients.

Methods: This is an open-label, prospective, non-randomized, single-centre pilot study that included patients with HCC that received Ho-SIRT if the work-up using Ho-scout showed a tumour-absorbed dose ≥150 Gy, a non-tumoural liver absorbed dose less than 60 Gy and a lung absorbed dose less than 30 Gy.

Development of an enzyme-linked immunosorbent assay for newborns dried blood spot thyroglobulin.

Background: Thyroglobulin (Tg) is a biomarker of iodine status. Newborn Tg is a more sensitive marker than neonatal TSH in detecting variations in iodine intake. This study aims to validate an enzyme-linked immunosorbent assay (ELISA) for Tg determination on dried blood spots (DBS) in newborns.

Impact of scatter correction on personalized dosimetry in selective internal radiotherapy using Ho-PLLA: a single-center study including Monte-Carlo simulation, phantom and patient imaging.

Background: Developments in transarterial radioembolization led to the conception of new microspheres loaded with holmium-166 (Ho). However, due to the complexity of the scatter components in Ho single photon emission computed tomography (SPECT), questions about image quality and dosimetry are emerging. The aims of this work are to investigate the scatter components and correction methods to propose a suitable solution, and to evaluate the impact on image quality and dosimetry including Monte-Carlo (MC) simulations, phantom, and patient data.

The ETA-ESE statement on the European Chemicals Agency opinion on iodine as an endocrine disruptor.

In 2022, the European Chemicals Agency (ECHA) made a statement concluding that iodine is an endocrine disruptor (ED). "We stress the fact that the ECHA opinion ECHA/BPC/357/2022 is based on their misguidedly zooming in on exclusively the biocidal products (e.g.